




Apoptosis Control to Extend and Enhance Life



FOR IMMEDIATE RELEASE

Contact:

Aegera Therapeutics, Inc.
514-288-5532, x227
Michael Atkin, President & CEO
E-mail: michael.atkin@aegera.com

OLSC Names Aegera As One Of Canada's Top Ten Biotechnology Investment And/Or Partnering Prospects For A Second Year

November 4, 2002. Ottawa, ONTARIO. At BioNorth 2002, the Ottawa Life Sciences Council (OLSC) announced the 2002 winners of a national competition to identify the best corporate investment and partnering prospects in the Canadian life sciences sector. Included in this exclusive and prestigious list was Aegera Therapeutics Inc., of Montreal, Quebec and Ottawa, Ontario.

Commenting on the award, Michael Atkin, President & CEO noted that "Aegera has now been recognized two years running by OLSC, which is a significant recognition of its dedicated research staff, in both Montreal and Ottawa, that are committed to meeting important medical needs for cancer and neurological diseases. Aegera remains fully committed to building on this string of successes and remaining a leader in its focus areas of apoptosis and signal transduction."

About Aegera

Aegera Therapeutics Inc. is a privately-held biotechnology company headquartered in Montreal, Canada, with a wholly owned Ottawa subsidiary – Aegera Oncology Inc. Aegera has built a strong, focused biotechnology company focused on apoptosis control to extend and enhance life: killing cancer cells by inducing apoptosis and rescuing neurons from cell death. Its lead oncology program is a XIAP antisense therapeutic which is expected to enter the clinic in Q1 2004. Aegera has in development two additional approaches to regulate apoptosis for cancer. In addition, it is also developing small molecular drugs to treat central and peripheral nerve diseases as well as a unique adult stem cell technology. For more information, please visit Aegera's website at www.aegera.com.
